EFFICACY OF BOTULINUM TOXIN TYPE A IONTOPHORESIS IN THE MASSETER MUSCLE FOR TREATMENT OF MYOFASCIAL PAIN DYSFUNCTION SYNDROME (A RANDOMIZED CONTROLLED CLINICAL STUDY) | ||||
Alexandria Dental Journal | ||||
Articles in Press, Corrected Proof, Available Online from 18 April 2024 PDF (731.83 K) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/adjalexu.2023.235890.1414 | ||||
View on SCiNiTO | ||||
Authors | ||||
Alaa Adel Ibrahim 1; Riham Mostafa Eldibany2; Lydia Nabil Melek3; Hoda Mohamed Abdel-Naby4 | ||||
145 street | ||||
2Oral and Maxillofacial Surgery, Faculty of Dentistry, Alexandria University | ||||
3Associate Professor, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Alexandria University, Egypt | ||||
4physical Medicine, Rheumatology and Rehabilitation Faculty of Medicine, Alexandria University, | ||||
Abstract | ||||
Background: Masticatory myofascial trigger points (TrPs) represent a major contributor to non-dental orofacial pain. The primary treatment for myofascial TrPs involves intramuscular injections, which can be painful and anxiety-inducing for patients. An alternative, pain-free treatment approach for myofascial pain is iontophoresis. Aim of this study: This study aimed to assess the efficacy of Botulinum toxin type A (BTX-A) Iontophoresis in managing muscle activity, Visual Analogue Scale (VAS) pain scores, mouth opening range, and Electromyography in individuals diagnosed with myofascial pain dysfunction syndrome (MPDS). Materials and methods: Twenty-two patients exhibiting symptoms of MPDS in the masseter muscle were included. These patients were randomly divided into two equal groups: the study group (n=11) received BTX-A iontophoresis, while the control group (n=11) received saline iontophoresis as a placebo. Muscle activity at rest and during function was assessed using VAS, the range of mouth opening was measured, and electromyography assessments were conducted. These assessments were performed pre-operatively and during all follow-up visits. Results: There analysis revealed no significant differences between the two groups at any of the measured timepoints (preoperative, immediate postoperative and 3-month follow-up) concerning pain levels, mouth opening or muscle activity. Conclusion: The current study revealed no significant differences between the BTX-A and saline groups in the treatment of MPDS by iontophoresis. | ||||
Keywords | ||||
Myofascial pain; Masseter muscle; trigger points; Botulinum toxin type A; iontophoresis | ||||
Statistics Article View: 22 PDF Download: 33 |
||||